SHM Converge Scientific Abstract ePoster Gallery-Hypercoaguability in Cancer Patients With Covid-19

Pdf Summary

This retrospective cohort study examined hospitalized patients with active cancer and COVID-19 at OSF St. Francis Medical Center (March–December 2020) to determine the incidence and clinical impact of thromboembolic events (TE) within 90 days.<br /><br />Among 78 patients, 12 (15.38%) developed a new TE, and all events occurred within 30 days of hospital admission. Arterial events were more common than venous events: 7 arterial events (8.9%) included 4 strokes, 1 mesenteric ischemia, and 2 NSTEMI/STEMI cases. There were 5 venous events, including 2 pulmonary emboli and 3 deep vein thromboses.<br /><br />Patients who experienced TE had significantly worse outcomes than those without TE. Mortality was higher in the TE group (63.9% vs 33.8%; OR 6.59, 95% CI 1.17–37.09, p=0.024), ICU admission was more frequent (87.4% vs 43.8%; OR 11.7, 95% CI 1.33–102.39, p<0.001), and hospital length of stay was longer (14.4 vs 10.1 days, p=0.001).<br /><br />Anticoagulation appeared to be associated with a lower incidence of TE. Events were much more frequent in patients receiving no anticoagulation compared with those on prophylactic or therapeutic anticoagulation.<br /><br />Overall, the study suggests that patients with both active cancer and COVID-19 have a substantial early risk of thromboembolic complications, particularly within the first 30 days, and that these events are associated with increased ICU use, longer hospitalization, and higher mortality.

Asset Subtitle

Rachel S. Zussman

Meta Tag

Author List Hanna M. Markewycz, Manasa Kandula, Min-Chul Kim, Rachel S. Zussman

Category Research

Concept Thromboembolism

Concept Cancer

Concept COVID-19

Concept Mortality

Concept Retrospective Cohort Study

Distinguished Non-Finalist

Presenter Organization University of Illinois College of Medicine-Peoria IL

Presenting Author Rachel S. Zussman

Track Outcomes Research

Keywords

active cancer

COVID-19

thromboembolic events

retrospective cohort study

hospitalized patients

arterial thrombosis

venous thrombosis

mortality

ICU admission

anticoagulation

Thromboembolism

Cancer

COVID-19

Mortality

Retrospective Cohort Study